In a surprising move, Gilead Sciences (GILD) early next year will begin selling so-called authorized generic versions of its two leading hepatitis C treatments — Epclusa and Harvoni — at significantly lower prices that the company claims will offer “substantial savings” to Medicaid and other patients.

The effort, which was met with intrigue on Wall Street but skepticism among patient advocates, comes as Gilead struggles to compete in a hepatitis C market that it once dominated with sky-high prices before rivals began undercutting its market share with lower pricing.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Ah, a wonderful phrase – “another round of pricing flux” – as if the market pricing system weren’t acknowledged as already “Fluxxed,” as it were,

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy